Safety and efficacy profile of ozenoxacin 1% cream in pediatric patients with impetigo.
Antibiotic
Impetigo
Ozenoxacin
Pediatrics
Safety
Topical
Journal
International journal of women's dermatology
ISSN: 2352-6475
Titre abrégé: Int J Womens Dermatol
Pays: United States
ID NLM: 101654170
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
06
06
2019
revised:
16
09
2019
accepted:
23
10
2019
entrez:
8
4
2020
pubmed:
8
4
2020
medline:
8
4
2020
Statut:
epublish
Résumé
Ozenoxacin is a topical antibiotic approved in the United States for treatment of impetigo in adults and children age ≥2 months. This analysis evaluated the efficacy and safety of ozenoxacin in specific pediatric age groups. Data for children aged 2 months to <18 years recruited from eight countries who had participated in phase 1 and 3 trials of ozenoxacin were extracted and analyzed by age range. Across studies, 644 pediatric patients with impetigo received ozenoxacin 1% cream (n = 287) or vehicle (n = 247). One study included retapamulin 1% ointment as the internal validity control (n = 110). The clinical success rate at the end of treatment and bacterial eradication rates after 3 to 4 days of treatment and at the end of treatment were significantly higher with ozenoxacin than vehicle (all The results of this analysis suggest that ozenoxacin 1% cream is an effective and safe treatment for impetigo in pediatric patients aged 2 months to <18 years.
Sections du résumé
BACKGROUND
BACKGROUND
Ozenoxacin is a topical antibiotic approved in the United States for treatment of impetigo in adults and children age ≥2 months. This analysis evaluated the efficacy and safety of ozenoxacin in specific pediatric age groups.
METHODS
METHODS
Data for children aged 2 months to <18 years recruited from eight countries who had participated in phase 1 and 3 trials of ozenoxacin were extracted and analyzed by age range.
RESULTS
RESULTS
Across studies, 644 pediatric patients with impetigo received ozenoxacin 1% cream (n = 287) or vehicle (n = 247). One study included retapamulin 1% ointment as the internal validity control (n = 110). The clinical success rate at the end of treatment and bacterial eradication rates after 3 to 4 days of treatment and at the end of treatment were significantly higher with ozenoxacin than vehicle (all
CONCLUSION
CONCLUSIONS
The results of this analysis suggest that ozenoxacin 1% cream is an effective and safe treatment for impetigo in pediatric patients aged 2 months to <18 years.
Identifiants
pubmed: 32258344
doi: 10.1016/j.ijwd.2019.10.008
pii: S2352-6475(19)30116-9
pmc: PMC7105648
doi:
Types de publication
Journal Article
Langues
eng
Pagination
109-115Informations de copyright
© 2019 Published by Elsevier Inc. on behalf of Women's Dermatologic Society.
Références
Future Microbiol. 2014;9(9):1013-23
pubmed: 25340832
Future Microbiol. 2014;9(8 Suppl):S33-40
pubmed: 25209523
J Antimicrob Chemother. 2015 Oct;70(10):2681-92
pubmed: 26142407
Antimicrob Agents Chemother. 2007 Nov;51(11):3880-6
pubmed: 17724154
Antimicrob Agents Chemother. 2015;59(6):3350-6
pubmed: 25824213
Future Microbiol. 2018 May 1;13:3-19
pubmed: 29745242
JAMA Dermatol. 2018 Jul 1;154(7):806-813
pubmed: 29898217
Antimicrob Agents Chemother. 2013 Dec;57(12):6389-92
pubmed: 24080666
BMJ. 2004 Jul 10;329(7457):95-9
pubmed: 15242915
Mayo Clin Proc. 2011 Nov;86(11):1113-23
pubmed: 22033257
Expert Opin Pharmacother. 2005 Oct;6(13):2245-56
pubmed: 16218885
Future Microbiol. 2014;9(8 Suppl):S11-6
pubmed: 25209519
Future Microbiol. 2018 May 1;13:31-40
pubmed: 29745239
Antimicrob Agents Chemother. 2010 Sep;54(9):3614-7
pubmed: 20566766
Future Microbiol. 2014;9(8 Suppl):S23-31
pubmed: 25209521
Antimicrob Agents Chemother. 2011 May;55(5):2431-3
pubmed: 21282426
PLoS One. 2015 Aug 28;10(8):e0136789
pubmed: 26317533
Int J Antimicrob Agents. 2010 Mar;35(3):282-7
pubmed: 20036520
J Antimicrob Chemother. 2010 Jul;65(7):1353-8
pubmed: 20430787
Acta Derm Venereol. 2010;90(1):52-7
pubmed: 20107726
Expert Rev Anti Infect Ther. 2019 Mar;17(3):159-168
pubmed: 30686133
Clin Infect Dis. 2006 Feb 1;42(3):394-400
pubmed: 16392088
Am Fam Physician. 2007 Mar 15;75(6):859-64
pubmed: 17390597
Clin Infect Dis. 2014 Jul 15;59(2):147-59
pubmed: 24947530
Int J Dermatol. 2003 Apr;42(4):251-5
pubmed: 12694487